리라글루티드 및 세마글루티드 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global liraglutide and semaglutide market size is expected to reach USD 53.39 Billion in 2034 from USD 19.82 Billion in 2025, growing at a CAGR of 11.64 during 2026-2034.This market is witnessing robust growth due to increasing demand for effective treatments for type 2 diabetes and obesity. Liraglutide and semaglutide are glucagon-like peptide-1 receptor agonists that help regulate blood glucose levels and support weight management. Rising prevalence of diabetes, obesity, and related metabolic disorders is driving significant market expansion. Healthcare providers are increasingly prescribing these therapies due to their proven efficacy and favorable clinical outcomes.

Growing awareness of chronic disease management and preventive healthcare is supporting adoption across various patient populations. Pharmaceutical companies are investing heavily in product development, expanded indications, and innovative delivery methods to strengthen market presence. Favorable clinical research findings and increasing reimbursement support are further contributing to demand. The expanding focus on obesity treatment is also creating additional growth opportunities for these therapies.

Future prospects remain highly promising as global healthcare systems prioritize metabolic disease management. Ongoing clinical studies exploring cardiovascular and additional therapeutic benefits are expected to expand treatment applications. Increasing healthcare access in emerging markets will further enhance market penetration. As obesity and diabetes rates continue to rise worldwide, demand for liraglutide and semaglutide therapies is likely to grow significantly.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• Pills (Oral Tablets (Liraglutide, Semaglutide), Extended-Release Oral Formulations)
• Liquid (Injectable Solutions (Liraglutide, Semaglutide), Pre-Filled Syringes, Vials For Injection)

By Administration

• Parenteral
• Oral

By Application

• Type 2 Diabetes Mellitus
• Obesity
• Other Applications

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Merck & Co., Inc., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Sanofi, Novartis AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Limited, Biocon Limited, Viatris Inc., Cipla Limited, Lupin Limited

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL LIRAGLUTIDE AND SEMAGLUTIDE MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Pills (Oral Tablets (Liraglutide, Semaglutide), Extended-Release Oral Formulations) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Liquid (Injectable Solutions (Liraglutide, Semaglutide), Pre-Filled Syringes, Vials For Injection) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL LIRAGLUTIDE AND SEMAGLUTIDE MARKET: BY ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Administration
• 5.2. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL LIRAGLUTIDE AND SEMAGLUTIDE MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Type 2 Diabetes Mellitus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Obesity Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL LIRAGLUTIDE AND SEMAGLUTIDE MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL LIRAGLUTIDE AND SEMAGLUTIDE MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Type
  • 8.2.2 By Administration
  • 8.2.3 By Application
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Type
  • 8.3.2 By Administration
  • 8.3.3 By Application
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Type
  • 8.4.2 By Administration
  • 8.4.3 By Application
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Type
  • 8.5.2 By Administration
  • 8.5.3 By Application
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Type
  • 8.6.2 By Administration
  • 8.6.3 By Application
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL LIRAGLUTIDE AND SEMAGLUTIDE INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Novo Nordisk A/S
  • 10.2.2 Eli Lilly And Company
  • 10.2.3 Pfizer Inc
  • 10.2.4 Merck & Co.Inc
  • 10.2.5 AstraZeneca PLC
  • 10.2.6 Boehringer Ingelheim International GmbH
  • 10.2.7 Sanofi
  • 10.2.8 Novartis AG
  • 10.2.9 Teva Pharmaceutical Industries Ltd
  • 10.2.10 Sun Pharmaceutical Industries Limited
  • 10.2.11 Dr. Reddy's Laboratories Limited
  • 10.2.12 Biocon Limited
  • 10.2.13 Viatris Inc
  • 10.2.14 Cipla Limited
  • 10.2.15 Lupin Limited